Experimental Therapy Halts Treatment-resistant Brain Tumors
Researchers report lab breakthrough in human cells, mouse models for high grade gliomas
The protein encoded by the Olig2 gene is present in a vast majority of gliomas. Researchers have found that using a gene therapy can halt the growth of gliomas in both human cells and mouse models. Removing the Olig2 gene stops further tumor grown. Even further, removing or eliminating the Olig2-producing cells block any type of tumor formation. “We find that elimination of dividing Olif2-expressing cells block initiation and progression of glioma in animal models and further show that Olig2 is the molecular arbiter of genetic adaptability that makes high-grade gliomas aggressive and treatment resistant,” said Qing Richard Lu, PhD, lead investigator and scientific director of the Brain Tumor Center at Cincinnati Children’s. “By finding a way to inhibit Olig2 in tumor forming cells, we were able to change that tumor cells’ makeup and sensitize them to targeting molecular treatment. This suggests a proof for stratified therapy in distinct subtypes of malignant gliomas.” To read more, click here.
Microsurgery Course Zurich
March 29-April 1, 2017; Zurich, Switzerland
12th World Congress on Brain Injury
March 29-April 1, 2017; New Orleans
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.